MedTrace Logo

The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure

NCT00043836 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-09-02

No results posted yet for this study

Summary

The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic heart failure (DHF), and that the improvements in exercise tolerance will correlate with the improvements in aortic distensibility.

Conditions

  • Heart Failure, Congestive
  • Dyspnea
  • Pulmonary Edema

Interventions

DRUG

ALT-711

Sponsors & Collaborators

  • Synvista Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Dalane W Kitzman, MD · Associate Professor of Medicine and Cardiology, Wake Forest University Baptist Medical Center

  • Michael R Zile, MD · Charles Ezra Daniel Professor of Medicine, Medical University of South Carolina

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2003-02-28
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00043836 on ClinicalTrials.gov